



**FOR IMMEDIATE RELEASE**

## **SPARC enters into a licensing agreement with Biomodifying to acquire exclusive rights for antibody against unique oncology target**

**MUMBAI – December 3, 2021**, Sun Pharma Advanced Research Company Ltd. (SPARC) (Reuters: SPRC.BO, Bloomberg: SPADV IN, NSE: SPARC, BSE: 532872) today announced that it has entered into an agreement with Biomodifying LLC (Biomodifying) to exclusively license Biomodifying's intellectual property, including all patents and patent applications owned or controlled by Biomodifying, along with antibodies developed for multiple uses including for cancer.

Under the agreement, Biomodifying is eligible for an up-front payment, milestone payments on pre-specified clinical, regulatory, and commercial milestones, as well as royalties on sales. In addition, SPARC will pay Biomodifying a percentage of payments received for sublicenses of the licensed IP.

"This is an important milestone for SPARC. The licensing of antibodies from Biomodifying will assist us in our endeavour to transition SPARC into a company focussed on novel treatment modalities, including bi-specific antibodies and antibody drug conjugates" said Anil Raghavan, CEO of SPARC.

### **About SPARC (CIN: L73100GJ2006PLC047837):**

Sun Pharma Advanced Research Company Ltd. (SPARC) is a pharmaceutical company focused on continuously improving standards of care for patients globally through innovation in therapeutics and delivery. SPARC consistently aims to lower costs and improve operational efficiencies to advance availability and affordability of cures for patients across the world. More information about the company can be found at [www.sparc.life](http://www.sparc.life)

### **About Biomodifying LLC (FL L05000052690):**

Biomodifying, LLC is a biotech company dedicated to identifying and exploiting molecules over-expressed by cancer cells by developing next generation novel therapies that specifically target tumors while sparing normal, non-cancerous tissues – an approach that is expected to contribute to the development of therapies less harsh and more adapted to larger patient populations than currently used chemotherapy regimens.

**Sun Pharma Advanced Research Company Ltd.**

17/B, Mahal Industrial Estate, Off Mahakali Caves Road, Andheri (East), Mumbai 400 093, Maharashtra, India.  
Tel.: (91-22) 6645 5645 | Fax.: (91-22) 6645 5685 | CIN: L73100GJ2006PLC047837 | Website: [www.sparc.life](http://www.sparc.life)

Registered office : Plot no. 5&6/1, Savli GIDC Estate, Manjusar 391775, District: Vadodara, Gujarat, India.



**Disclaimer:**

Statements in this document describing the Company's objectives, projections, estimates, expectations, plans or predictions or industry conditions or events may be "forward looking statements" within the meaning of applicable securities laws and regulations. Actual results, performance or achievements could differ materially from those expressed or implied.

**Media Contact:**

Jaydeep Issrani

Tel +91 22 66455645, Ext: 5787

Tel Direct +91 22 6645 5787

Mobile +91-9820216916

E-mail [jaydeep.issrani@sparcmail.com](mailto:jaydeep.issrani@sparcmail.com)

*®, TM - All brand names and trademarks are the property of respective owners.*